{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:18:23Z","timestamp":1781871503071,"version":"3.54.5"},"reference-count":46,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dutch Heart Foundation","award":["2001-005"],"award-info":[{"award-number":["2001-005"]}]},{"name":"Dutch Heart Foundation","award":["E.033"],"award-info":[{"award-number":["E.033"]}]},{"name":"University Medical Center Groningen","award":["2001-005"],"award-info":[{"award-number":["2001-005"]}]},{"name":"University Medical Center Groningen","award":["E.033"],"award-info":[{"award-number":["E.033"]}]},{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["2001-005"],"award-info":[{"award-number":["2001-005"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["E.033"],"award-info":[{"award-number":["E.033"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fibroblast growth factor 21 (FGF21) and ketone bodies are markers of metabolic dysregulation, independently associated with metabolic-dysfunction-associated steatotic liver disease (MASLD) and mortality. We studied their interaction with MASLD and all-cause mortality in 6025 participants from the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort. Plasma FGF21 (immunoassay) and ketone body concentrations (nuclear magnetic resonance spectroscopy) were measured at baseline. A Fatty Liver Index \u226560 was used as a proxy of MASLD. Logistic regression assessed associations with MASLD, and Cox models evaluated all-cause mortality over a median follow-up of 10.3 years. FGF21 and ketone bodies were not correlated (r = 0.02, p = 0.06), but FGF21 (OR: 1.93 [1.81\u20132.05], p &lt; 0.001) and ketone bodies (OR: 1.29 [1.19\u20132.05], p &lt; 0.001) were independent of each other associated with MASLD, with a positive interaction (p = 0.004). Higher FGF21 (HR: 1.24, 95% CI: 1.16\u20131.32, p &lt; 0.001) and ketone bodies (HR: 1.46, 95% CI: 1.34\u20131.59, p &lt; 0.001) were associated with mortality, as well as with a positive interaction (p = 0.038). After adjustment for potential confounders, only ketone bodies remained independently associated, while the association of FGF21 became dependent on ketone body levels (interaction p = 0.005). These biomarkers may serve as integrated metabolic stress markers, improving risk stratification for MASLD and adverse outcomes.<\/jats:p>","DOI":"10.3390\/ijms26115059","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T20:26:50Z","timestamp":1748204810000},"page":"5059","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating FGF21 and Ketone Bodies Modify the Risk of MASLD and Mortality: Insights from the PREVEND Cohort Study"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4310-5657","authenticated-orcid":false,"given":"Mateo","family":"Chvatal-Medina","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Dam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3917-592X","authenticated-orcid":false,"given":"Margery A.","family":"Connelly","sequence":"additional","affiliation":[{"name":"Labcorp, 100 Perimeter Park, Morrisville, NC 27560, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4764-0246","authenticated-orcid":false,"given":"Han","family":"Moshage","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3356-6791","authenticated-orcid":false,"given":"Stephan J. L.","family":"Bakker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3844-5254","authenticated-orcid":false,"given":"Robin P. F.","family":"Dullaart","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-1627","authenticated-orcid":false,"given":"Adrian","family":"Post","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1016\/j.clnu.2021.01.036","article-title":"Fibroblast growth factor 21 and protein energy wasting in hemodialysis patients","volume":"40","author":"Post","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1210\/clinem\/dgac729","article-title":"Circulating FGF21 Concentration, Fasting Plasma Glucose, and the Risk of Type 2 Diabetes: Results From the PREVEND Study","volume":"108","author":"Post","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"H1029","DOI":"10.1152\/ajpheart.00527.2015","article-title":"Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21","volume":"309","author":"Domouzoglou","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/a-1778-4159","article-title":"FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance","volume":"54","year":"2022","journal-title":"Horm. Metab. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.tem.2019.05.007","article-title":"Going Back to the Biology of FGF21: New Insights","volume":"30","author":"Lewis","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the Physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu. Rev. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Veneti, S., Grammatikopoulou, M.G., Kintiraki, E., Mintziori, G., and Goulis, D.G. (2023). Ketone Bodies in Diabetes Mellitus: Friend or Foe?. Nutrients, 15.","DOI":"10.3390\/nu15204383"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<412::AID-DMRR72>3.0.CO;2-8","article-title":"Ketone bodies: A review of physiology, pathophysiology and application of monitoring to diabetes","volume":"15","author":"Laffel","year":"1999","journal-title":"Diabetes\/Metabolism Res. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/db22-0826","article-title":"Fasting Ketone Bodies and Incident Type 2 Diabetes in the General Population","volume":"72","author":"Garcia","year":"2023","journal-title":"Diabetes"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e006885","DOI":"10.1161\/JAHA.117.006885","article-title":"Association Between Circulating Ketone Bodies and Worse Outcomes in Hemodialysis Patients","volume":"6","author":"Obokata","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e13627","DOI":"10.1111\/eci.13627","article-title":"Nonalcoholic fatty liver disease, circulating ketone bodies and all-cause mortality in a general population-based cohort","volume":"51","author":"Post","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Garcia, E., Shalaurova, I., Matyus, S.P., Oskardmay, D.N., Otvos, J.D., Dullaart, R.P., and Connelly, M.A. (2020). Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020321"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Palm, C.L., Shalaurova, I., Connelly, M.A., Bakker, S.J.L., Westenbrink, B.D., and Dullaart, R.P.F. (2024). Fasting Plasma Ketone Bodies Are Associated with NT-proBNP: A Potential Mechanism to Provide Fuel for the Failing Heart. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061541"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jacc.2021.07.054","article-title":"Association of Circulating Ketone Bodies with Functional Outcomes After ST-Segment Elevation Myocardial Infarction","volume":"78","author":"Westenbrink","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e13468","DOI":"10.1111\/eci.13468","article-title":"Association of beta-hydroxybutyrate with development of heart failure: Sex differences in a Dutch population cohort","volume":"51","author":"Westenbrink","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"153994","DOI":"10.1016\/j.metabol.2019.153994","article-title":"Fibroblast growth factor 21 in non-alcoholic fatty liver disease","volume":"101","author":"Tucker","year":"2019","journal-title":"Metabolism"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"117799","DOI":"10.1016\/j.cca.2024.117799","article-title":"Association of circulating fibroblast growth factor 21 levels with all-cause and cardiovascular mortality: The multi-ethnic study of atherosclerosis","volume":"555","author":"Tucker","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yang, M., Liu, C., Jiang, N., Liu, Y., Luo, S., Li, C., Zhao, H., Han, Y., Chen, W., and Li, L. (2023). Fibroblast growth factor 21 in metabolic syndrome. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1220426"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell Metab."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tezze, C., Romanello, V., and Sandri, M. (2019). FGF21 as Modulator of Metabolism in Health and Disease. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.00419"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2337\/db21-0363","article-title":"Hepatic CPT1A Facilitates Liver-Adipose Cross-Talk via Induction of FGF21 in Mice","volume":"71","author":"Sun","year":"2021","journal-title":"Diabetes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1111\/bph.15099","article-title":"Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21\/PGC-1\u03b1 pathway","volume":"177","author":"Wu","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Watanabe, M., Risi, R., Camajani, E., Contini, S., Persichetti, A., Tuccinardi, D., Ernesti, I., Mariani, S., Lubrano, C., and Genco, A. (2020). Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study. Nutrients, 12.","DOI":"10.3390\/nu12072141"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/db09-1878","article-title":"Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats","volume":"59","author":"Sarruf","year":"2010","journal-title":"Diabetes"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.clnu.2016.04.027","article-title":"FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss","volume":"36","author":"Domingo","year":"2017","journal-title":"Clin. Nutr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.12688\/f1000research.14117.1","article-title":"Defining \u201cFGF21 Resistance\u201d during obesity: Controversy, criteria and unresolved questions","volume":"7","author":"Markan","year":"2018","journal-title":"F1000Research"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41467-017-02677-9","article-title":"Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","article-title":"Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics","volume":"25","author":"Puchalska","year":"2017","journal-title":"Cell Metab."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kolb, H., Kempf, K., R\u00f6hling, M., Lenzen-Schulte, M., Schloot, N.C., and Martin, S. (2021). Ketone bodies: From enemy to friend and guardian angel. BMC Med., 19.","DOI":"10.1186\/s12916-021-02185-0"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1038\/ncomms4944","article-title":"The \u03b2-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages","volume":"5","author":"Rahman","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/07435800.2020.1831015","article-title":"Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans","volume":"46","author":"Lauritzen","year":"2021","journal-title":"Endocr. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103415","DOI":"10.1016\/j.mcn.2019.103415","article-title":"Fibroblast growth Factor-21 promotes ketone body utilization in neurons through activation of AMP-dependent kinase","volume":"101","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kawakami, R., Sunaga, H., Iso, T., Kaneko, R., Koitabashi, N., Obokata, M., Harada, T., Matsui, H., Yokoyama, T., and Kurabayashi, M. (2022). Ketone body and FGF21 coordinately regulate fasting-induced oxidative stress response in the heart. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-10993-4"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cmet.2007.05.010","article-title":"FGF21: A missing link in the biology of fasting","volume":"5","author":"Reitman","year":"2007","journal-title":"Cell Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1681\/ASN.V11101882","article-title":"Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population","volume":"11","author":"Janssen","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.09.006","article-title":"Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: The PREVEND study","volume":"243","author":"Kunutsor","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.atherosclerosis.2009.07.042","article-title":"High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: Possible attenuation of cardioprotection asso-ciated with high HDL cholesterol","volume":"208","author":"Dullaart","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"155666","DOI":"10.1016\/j.metabol.2023.155666","article-title":"Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study","volume":"147","author":"Kouvari","year":"2023","journal-title":"Metabolism"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., and Tiribelli, C. (2006). The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol., 6.","DOI":"10.1186\/1471-230X-6-33"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Crudele, L., De Matteis, C., Novielli, F., Di Buduo, E., Petruzzelli, S., De Giorgi, A., Antonica, G., Berardi, E., and Moschetta, A. (2024). Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men. Biol. Sex Differ., 15.","DOI":"10.1186\/s13293-024-00617-z"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/sim.2787","article-title":"Multiple imputation: Review of theory, implementation and software","volume":"26","author":"Harel","year":"2007","journal-title":"Stat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5059\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:39:40Z","timestamp":1760031580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26115059"],"URL":"https:\/\/doi.org\/10.3390\/ijms26115059","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]}}}